November 29, 2022 4:54pm

As the sector’s oversold popped with “ruled’ algorithms being their friend until the closing hour

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes.

Pre-open Indications: 2 Hits and 5 Miss

The Biostage (OTCQB: BSTG) Chronicles: the pump and promote is back +$0.50 with 6,259 shares traded; Hong Yu, DST's funding "head" is also president of BSTG - a conflict??? 

Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write

Your portfolio should be profiting from RMi’s analysis; subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! 

 

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +1.02 points (0.00%), the S&P close DOWN -6.36 points (-0.16%) while the Nasdaq closed DOWN -65.72 points (-0.59%)

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies

Indexes were mixed on Tuesday, ahead of an upcoming speech by U.S. Fed Chair Powell that could provide hints about magnitude of future interest rate hikes.

  • Powell is due to speak at a Brookings Institution event on Wednesday about the outlook for the U.S. economy and the labor market. Investors will be looking for clues about when the Fed will slow the pace of its aggressive interest rate hikes

Economic Data Docket: U.S. Conference Board’s consumer confidence eased further in November amid persistent worries about the rising cost of living.

  • When you have a handful of big catalysts (data on jobs, labor and inflation) in the near term, coming Wednesday – tomorrow; the market will trade sideways in anticipation of those events and it did.

 

Tuesday’s … RegMed Investor’s (RMi) Pre-Open: “post carnage, wishful thinking. Attempts to roll share pricing to the upside.” … https://www.regmedinvestors.com/articles/12719

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened

  • Tuesday’s advance/decline line opened positive at 23 up/ 10 down and 2 flats, stayed positive with 21 up/ 14 down and 0 flat at the mid-day, went neutral at 3 p.m. 17/17 and 0 flat, ending with a negative close of 15/17 and 2 flats.
  • Monday’s advance/decline line opened negative at 12 up/ 21 down and 2 flats, stayed negative with 14 up/ 21 down and 0 flat at the mid-day, ending with a negative close of 7/27 and 1 flat.

 

Pre-open indication results: 2 Hits < Verve Therapeutics (VERV -$0.10), Caribou Biosciences (CRBU -$0.07)> and 5 Miss < Prime Therapeutics (PRME -$0.11), CRISPR Therapeutics (CRSP -$0.46), Intellia Therapeutics (NTLA -$0.26), Beam Therapeutics (BEAM +$0.43), Ultragenyx (RARE +$0.27)

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was down -0.47% and the XBI was up +0.41%
  • Monday, the IBB was down -0.69% and the XBI was down -1.74%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.36 points or -1.62% at 21.85
  • Monday was up +1.70 points or +8.29% at 22.20

 

Closing Down (10 or 17):

  • Alnylam Pharmaceuticals (ALNY -$4.41 after Monday’s -$3.52),
  • uniQure NV (QURE -$1.63 after Monday’s +$0.42),
  • Ionis Pharmaceuticals (IONS -$1.57 after Monday’s -$1.23),
  • BioLife Solutions (BLFS -$0.77 after Monday’s -$0.57),
  • Crisper Therapeutics (CRSP -$0.46 after Monday’s -$1.65),
  • Intellia Therapeutics (NTLA -$0.26 after Monday’s -$1.42),
  • Caribou Biosciences (CRBU -$0.20),
  • Regenxbio (RGNX -$0.13 after Monday’s -$0.08),
  • Prime Therapeutics (PRME -$0.11 after Monday’s -$3.27),
  • Verve Therapeutics (VERV -$0.10),

Flat (1):

  • Homology Medicine (FIXX),
  • Adverum Biotechnologies (ADVM)

Closing Up (10 of 15):

  • Fate Therapeutics (FATE +$0.58 after Monday’s -$0.57),
  • Sage Therapeutics (SAGE +$0.56 after Monday’s +$0.13),
  • Biostage (BSTG +$0.50),
  • Beam Therapeutics (BEAM +$0.43 after Monday’s -$1.10),
  • bluebird bio (BLUE +$0.28),
  • Ultragenyx (RARE +$0.27),
  • Compass Therapeutics (CMPX +$0.19),
  • Vericel (VCEL +$0.12 after Monday’s -$0.46),
  • AxoGen (AXGN +$0.12 after Monday’s -$0.78),
  • Sangamo Therapeutics (SGMO +$0.07),

 

Q4 – November

  • Tuesday closed negative with 15 incliner, 17 decliners and 2 flats
  • Monday closed negative with 7 incliner, 27 decliners and 1 flat

 

The BOTTOM LINE: I try to keep it simple … and short!

There are still reasons to be cautious about the current market. The sector got a stiff upward move yet, lost altitude of upsiders as the session hit 3 p.m. to close negative at the close!

Investors should be playing this market, but not for all the marbles.

Just 23 trading days remain in 2022.

At any given time, not many stocks are flashing buy signals, while shakeouts and sector rotations can make holding onto positions difficult.

Avrobio (AVRO -$0.0021) filed a S-3 for $250 million common stock, preferred stock, debt securities, warrants and unit offering within draft prospectus by Cowen as stock sinks while delisting continues? Just another “screw-job” of investors! < Read, SELL and Weep - see hyperlink below> Avrobio (AVRO) files S-3 (Registration Statement) for offering with draft prospectus by Cowen … https://investors.avrobio.com/node/9116/html

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.